Elpiscience has a robust pipeline of next-generation cancer immunotherapies, including six clinical-stage programs, focused on removing immunosuppressive factors and reinvigorating exhausted T cells in the tumor microenvironment (TME).
- Assets with greater China rights
- Assets with global rights
- Removing immune suppressive factors in TME
- Re-invigorating exhausted T cells
-
AssetTargetProgramDiscoveryPreclinicalPh1Ph2Ph3
-
ES104VEGF/DLL4
- +chemo
-
ES102OX40
- +PD-1
-
ES1014-1BB/PD-L1
- Monotherapy/Combo
-
ES002CD39
- Monotherapy/Combo
-
ES014CD39/TGF-β
- Monotherapy
-
ES009LILRB2
- Monotherapy/Combo
-
ES004SIRPα
- Monotherapy/Combo
-
ES005LAG3
- Monotherapy/Combo
-
ES008LILRB1
- Monotherapy/Combo
-
ES019SIRPα/PD-L1
- Monotherapy
-
ES028SIRPα/CLDN18.2
- Monotherapy
-
View MoreES104TargetVEGF/DLL4
- Discovery Preclinical Ph1 Ph2 Ph3
-
+chemo
-
View MoreES102TargetOX40
- Discovery Preclinical Ph1 Ph2 Ph3
-
+PD-1
-
View MoreES101Target4-1BB/PD-L1
- Discovery Preclinical Ph1 Ph2 Ph3
-
Monotherapy/
Combo
-
View MoreES002TargetCD39
- Discovery Preclinical Ph1 Ph2 Ph3
-
Monotherapy/
Combo
-
View MoreES014TargetCD39/TGF-β
- Discovery Preclinical Ph1 Ph2 Ph3
-
Monotherapy
-
View MoreES009TargetLILRB2
- Discovery Preclinical Ph1 Ph2 Ph3
-
Monotherapy/
Combo
-
View MoreES004TargetSIRPα
- Discovery Preclinical Ph1 Ph2 Ph3
-
Monotherapy/
Combo
-
View MoreES005TargetLAG3
- Discovery Preclinical Ph1 Ph2 Ph3
-
Monotherapy/
Combo
-
View MoreES008TargetLILRB1
- Discovery Preclinical Ph1 Ph2 Ph3
-
Monotherapy/Combo
-
View MoreES019TargetSIRPα/PD-L1
- Discovery Preclinical Ph1 Ph2 Ph3
-
Monotherapy
-
View MoreES028TargetSIRPα/CLDN18.2
- Discovery Preclinical Ph1 Ph2 Ph3
-
Monotherapy
